López Enrique, Steiner Alexander J, Manier Karra, Shapiro Bryan B, Vanle Brigitte, Parisi Thomas, Dang Jonathan, Chang Tiffany, Ganjian Shaina, Mirocha James, Danovitch Itai, IsHak Waguih William
Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
J Affect Disord. 2018 Jan 1;225:117-122. doi: 10.1016/j.jad.2017.08.031. Epub 2017 Aug 14.
Similar rates of remission from Major Depressive Disorder (MDD) have been documented between ethnic groups in response to antidepressant treatment. However, ethnic differences in functional outcomes, including patient-reported quality of life (QOL) and functioning, have not been well-characterized. We compared symptomatic and functional outcomes of antidepressant treatment in Hispanic and non-Hispanic patients with MDD.
We analyzed 2280 nonpsychotic treatment-seeking adults with MDD who received citalopram monotherapy in Level 1 of the Sequenced Treatment Alternatives to Relieve Depression study. All subjects (239 Hispanic, 2041 non-Hispanic) completed QOL, functioning, and depressive symptom severity measures at entry and exit.
Hispanic participants had significantly worse QOL scores at entry and exit (p < 0.01). However, after controlling for baseline QOL, there was no difference between Hispanic and non-Hispanic patients' QOL at exit (p = 0.21). There were no significant between-group differences at entry or at exit for depressive symptom severity or functioning. Both groups had significant improvements in depressive symptom severity, QOL, and functioning from entry to exit (all p values < 0.01). Patients with private insurance had lower depressive symptom severity, greater QOL, and better functioning at exit compared to patients without private insurance.
This study was a retrospective data analysis, and the Hispanic group was relatively small compared to the non-Hispanic group.
Hispanic and non-Hispanic participants with MDD had similar responses to antidepressant treatment as measured by depressive symptom severity scores, quality of life, and functioning. Nevertheless, Hispanic patients reported significantly worse quality of life at entry.
在接受抗抑郁治疗时，不同种族群体的重度抑郁症（MDD）缓解率相似。然而，包括患者报告的生活质量（QOL）和功能在内的功能结局方面的种族差异尚未得到充分描述。我们比较了西班牙裔和非西班牙裔MDD患者抗抑郁治疗的症状和功能结局。
我们分析了2280名寻求治疗的非精神病性MDD成年患者，他们在缓解抑郁症的序贯治疗替代方案研究的第1阶段接受了西酞普兰单药治疗。所有受试者（239名西班牙裔，2041名非西班牙裔）在入组和出组时完成了生活质量、功能和抑郁症状严重程度的测量。
西班牙裔参与者在入组和出组时的生活质量得分显著更差（p < 0.01）。然而，在控制基线生活质量后，西班牙裔和非西班牙裔患者出组时的生活质量没有差异（p = 0.21）。在入组或出组时，抑郁症状严重程度或功能方面没有显著的组间差异。两组从入组到出组在抑郁症状严重程度、生活质量和功能方面都有显著改善（所有p值 < 0.01）。与没有私人保险的患者相比，有私人保险的患者出组时抑郁症状严重程度更低，生活质量更高，功能更好。
本研究是一项回顾性数据分析，与非西班牙裔组相比，西班牙裔组相对较小。
以抑郁症状严重程度评分、生活质量和功能衡量，患有MDD的西班牙裔和非西班牙裔参与者对抗抑郁治疗的反应相似。尽管如此，西班牙裔患者在入组时报告的生活质量明显更差。
